MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199

Targeted therapies designed to exploit specific molecular pathways in aggressive cancers are an exciting area of current research. Mixed Lineage Leukemia (MLL) mutations such as the t(4;11) translocation cause aggressive leukemias that are refractory to conventional treatment. The t(4;11) translocat...

Full description

Bibliographic Details
Main Authors: Juliana M. Benito, Laura Godfrey, Kensuke Kojima, Leah Hogdal, Mark Wunderlich, Huimin Geng, Isabel Marzo, Karine G. Harutyunyan, Leonard Golfman, Phillip North, Jon Kerry, Erica Ballabio, Triona Ní Chonghaile, Oscar Gonzalo, Yihua Qiu, Irmela Jeremias, LaKiesha Debose, Eric O’Brien, Helen Ma, Ping Zhou, Rodrigo Jacamo, Eugene Park, Kevin R. Coombes, Nianxiang Zhang, Deborah A. Thomas, Susan O’Brien, Hagop M. Kantarjian, Joel D. Leverson, Steven M. Kornblau, Michael Andreeff, Markus Müschen, Patrick A. Zweidler-McKay, James C. Mulloy, Anthony Letai, Thomas A. Milne, Marina Konopleva
Format: Article
Language:English
Published: Elsevier 2015-12-01
Series:Cell Reports
Subjects:
apoptosis pathways
leukemias
bcl-2 family members
MLL/AF4
DOT1L
H3K79 methylation
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124715014151

Internet

http://www.sciencedirect.com/science/article/pii/S2211124715014151

Similar Items